Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Immobilization of actively thromboresistant assemblies on sterile blood-contacting surfaces.

Qu Z, Krishnamurthy V, Haller CA, Dorr BM, Marzec UM, Hurst S, Hinds MT, Hanson SR, Liu DR, Chaikof EL.

Adv Healthc Mater. 2014 Jan;3(1):30-5. doi: 10.1002/adhm.201300110. Epub 2013 Jun 21.

2.

Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates.

Perzborn E, Gruber A, Tinel H, Marzec UM, Buetehorn U, Buchmueller A, Heitmeier S, Laux V.

Thromb Haemost. 2013 Jul;110(1):162-72. doi: 10.1160/TH12-12-0907. Epub 2013 May 2.

PMID:
23636219
3.

A biologically active surface enzyme assembly that attenuates thrombus formation.

Qu Z, Muthukrishnan S, Urlam MK, Haller CA, Jordan SW, Kumar VA, Marzec UM, Elkasabi Y, Lahann J, Hanson SR, Chaikof EL.

Adv Funct Mater. 2011 Dec 20;21(24):4736-4743. Epub 2011 Sep 26.

4.

Safety and antithrombotic efficacy of moderate platelet count reduction by thrombopoietin inhibition in primates.

Tucker EI, Marzec UM, Berny MA, Hurst S, Bunting S, McCarty OJ, Gruber A, Hanson SR.

Sci Transl Med. 2010 Jun 23;2(37):37ra45. doi: 10.1126/scitranslmed.3000697.

5.

Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding site.

Jiao JA, Kelly AB, Marzec UM, Nieves E, Acevedo J, Burkhardt M, Edwards A, Zhu XY, Chavaillaz PA, Wong A, Wong JL, Egan JO, Taylor D, Rhode PR, Wong HC.

Thromb Haemost. 2010 Jan;103(1):224-33. doi: 10.1160/TH09-06-0400. Epub 2009 Oct 26.

6.

Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI.

Tucker EI, Marzec UM, White TC, Hurst S, Rugonyi S, McCarty OJ, Gailani D, Gruber A, Hanson SR.

Blood. 2009 Jan 22;113(4):936-44. doi: 10.1182/blood-2008-06-163675. Epub 2008 Oct 22.

7.

Capture of flowing endothelial cells using surface-immobilized anti-kinase insert domain receptor antibody.

Markway BD, McCarty OJ, Marzec UM, Courtman DW, Hanson SR, Hinds MT.

Tissue Eng Part C Methods. 2008 Jun;14(2):97-105. doi: 10.1089/ten.tec.2007.0300.

PMID:
18544026
8.

Procoagulant properties of flow fields in stenotic and expansive orifices.

Fallon AM, Dasi LP, Marzec UM, Hanson SR, Yoganathan AP.

Ann Biomed Eng. 2008 Jan;36(1):1-13. Epub 2007 Nov 6.

PMID:
17985244
9.

Fibrinogen gamma' chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway.

Lovely RS, Boshkov LK, Marzec UM, Hanson SR, Farrell DH.

Br J Haematol. 2007 Nov;139(3):494-503.

PMID:
17910639
10.

Thrombin formation in vitro in response to shear-induced activation of platelets.

Fallon AM, Marzec UM, Hanson SR, Yoganathan AP.

Thromb Res. 2007;121(3):397-406. Epub 2007 May 29.

PMID:
17532367
11.

Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates.

Gruber A, Marzec UM, Bush L, Di Cera E, Fernández JA, Berny MA, Tucker EI, McCarty OJ, Griffin JH, Hanson SR.

Blood. 2007 May 1;109(9):3733-40. Epub 2007 Jan 16.

12.

Flow and thrombosis at orifices simulating mechanical heart valve leakage regions.

Fallon AM, Shah N, Marzec UM, Warnock JN, Yoganathan AP, Hanson SR.

J Biomech Eng. 2006 Feb;128(1):30-9.

PMID:
16532615
13.

Factor VIIa inhibitors: chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model.

Young WB, Mordenti J, Torkelson S, Shrader WD, Kolesnikov A, Rai R, Liu L, Hu H, Leahy EM, Green MJ, Sprengeler PA, Katz BA, Yu C, Janc JW, Elrod KC, Marzec UM, Hanson SR.

Bioorg Med Chem Lett. 2006 Apr 1;16(7):2037-41. Epub 2006 Jan 18.

PMID:
16412633
14.

Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates.

Tanaka KA, Fernández JA, Marzec UM, Kelly AB, Mohri M, Griffin JH, Hanson SR, Gruber A.

Br J Haematol. 2006 Jan;132(2):197-203.

PMID:
16398653
15.

Bileaflet aortic valve prosthesis pivot geometry influences platelet secretion and anionic phospholipid exposure.

Travis BR, Marzec UM, Leo HL, Momin T, Sanders C, Hanson SR, Yoganathan AP.

Ann Biomed Eng. 2001 Aug;29(8):657-64.

PMID:
11556722
16.

The sensitivity of indicators of thrombosis initiation to a bileaflet prosthesis leakage stimulus.

Travis BR, Marzec UM, Ellis JT, Davoodi P, Momin T, Hanson SR, Harker LA, Yoganathan AP.

J Heart Valve Dis. 2001 Mar;10(2):228-38.

PMID:
11297211
17.

Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers.

Harker LA, Roskos LK, Marzec UM, Carter RA, Cherry JK, Sundell B, Cheung EN, Terry D, Sheridan W.

Blood. 2000 Apr 15;95(8):2514-22.

PMID:
10753829
18.

Effects of Mpl ligands on platelet production and function in nonhuman primates.

Harker LA, Marzec UM, Kelly AB.

Stem Cells. 1998;16 Suppl 2:107-19. Review.

19.

Platelet reactivity in depressed patients treated with paroxetine: preliminary findings.

Musselman DL, Marzec UM, Manatunga A, Penna S, Reemsnyder A, Knight BT, Baron A, Hanson SR, Nemeroff CB.

Arch Gen Psychiatry. 2000 Sep;57(9):875-82.

PMID:
10986551
20.

Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates.

Harker LA, Marzec UM, Kelly AB, Chronos NR, Sundell IB, Hanson SR, Herbert JM.

Circulation. 1998 Dec 1;98(22):2461-9.

PMID:
9832493
21.

Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor.

Harker LA, Marzec UM, Novembre F, Sundell IB, Waller EK, Karpatkin S, McClure HM, Kelly AB, Stead RB.

Blood. 1998 Jun 15;91(12):4427-33.

PMID:
9616135
22.

Ineffective platelet production in thrombocytopenic human immunodeficiency virus-infected patients.

Cole JL, Marzec UM, Gunthel CJ, Karpatkin S, Worford L, Sundell IB, Lennox JL, Nichol JL, Harker LA.

Blood. 1998 May 1;91(9):3239-46.

PMID:
9558379
23.

Reduction in stent and vascular graft thrombosis and enhancement of thrombolysis by recombinant Lys-plasminogen in nonhuman primates.

Sundell IB, Marzec UM, Kelly AB, Chronos NA, Petersen LC, Hanson SR, Hedner U, Harker LA.

Circulation. 1997 Aug 5;96(3):941-8.

PMID:
9264505
25.

Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons.

Runge MS, Harker LA, Bode C, Ruef J, Kelly AB, Marzec UM, Allen E, Caban R, Shaw SY, Haber E, Hanson SR.

Circulation. 1996 Sep 15;94(6):1412-22.

PMID:
8823001
26.

Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.

Harker LA, Marzec UM, Hunt P, Kelly AB, Tomer A, Cheung E, Hanson SR, Stead RB.

Blood. 1996 Jul 15;88(2):511-21.

PMID:
8695799
27.

Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates.

Harker LA, Hunt P, Marzec UM, Kelly AB, Tomer A, Hanson SR, Stead RB.

Blood. 1996 Mar 1;87(5):1833-44.

PMID:
8634430
28.

Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates.

Yokoyama T, Kelly AB, Marzec UM, Hanson SR, Kunitada S, Harker LA.

Circulation. 1995 Aug 1;92(3):485-91.

PMID:
7634464
29.

Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates.

Cadroy Y, Hanson SR, Kelly AB, Marzec UM, Evatt BL, Kunicki TJ, Montgomery RR, Harker LA.

Blood. 1994 Jun 1;83(11):3218-24.

PMID:
8193356
30.

Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection.

Scharf RE, Tomer A, Marzec UM, Teirstein PS, Ruggeri ZM, Harker LA.

Arterioscler Thromb. 1992 Dec;12(12):1475-87.

PMID:
1450179
31.

Hirudin interruption of heparin-resistant arterial thrombus formation in baboons.

Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA.

Blood. 1991 Mar 1;77(5):1006-12.

PMID:
1995089
32.

Heparin-resistant thrombus formation by endovascular stents in baboons. Interruption by a synthetic antithrombin.

Krpski WC, Bass A, Kelly AB, Marzec UM, Hanson SR, Harker LA.

Circulation. 1990 Aug;82(2):570-7.

PMID:
2372903
34.

Inhibition of thrombus formation in vivo by novel antiplatelet agent.

Marzec UM, Kelly AB, Hanson SR, Lasslo A, Harker LA.

Arteriosclerosis. 1990 May-Jun;10(3):367-71.

PMID:
2140503
35.

Agkistrodon piscivorus piscivorus platelet aggregation inhibitor: a potent inhibitor of platelet activation.

Chao BH, Jakubowski JA, Savage B, Chow EP, Marzec UM, Harker LA, Maraganore JM.

Proc Natl Acad Sci U S A. 1989 Oct;86(20):8050-4.

36.

Demonstration of single chain urokinase-type plasminogen activator on human platelet membrane.

Park S, Harker LA, Marzec UM, Levin EG.

Blood. 1989 May 1;73(6):1421-5.

PMID:
2653456
37.

Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon.

Hanson SR, Pareti FI, Ruggeri ZM, Marzec UM, Kunicki TJ, Montgomery RR, Zimmerman TS, Harker LA.

J Clin Invest. 1988 Jan;81(1):149-58.

38.

Alterations in the serotonin release response in mechanically injured platelets.

Bernstein EF, Marzec UM.

Thromb Res. 1980 Oct 1;20(1):1-12. No abstract available.

PMID:
7209868
39.

Renin secretion in the chronically perfused pulseless calf. Evidence for failure of stimulation by decreased pulse pressure.

Shoor PM, Marzec UM, Griffith LD, Hammill FS, Dilley RB, Bernstein EF.

Circ Res. 1979 Jul;45(1):100-7.

PMID:
445691
40.

Altered serotonin release response in mechanically-injured platelets.

Marzec UM, Bernstein EF.

Trans Am Soc Artif Intern Organs. 1979;25:133-7. No abstract available.

PMID:
524571
41.
42.

Renin secretion during nonpulsatile left ventricular bypass in the awake calf.

Shoor PM, Marzec UM, Griffith LF, Hammill F, Dilley RB, Bernstein EF.

Surg Forum. 1978;29:120-1. No abstract available.

PMID:
401403

Supplemental Content

Loading ...
Support Center